Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GBSC: Graph-Based Sequence Clustering method for similar short tandem repeats in protein sequences.

Bioinformatics (Oxford, England)·2026
Same author

eHealth4U: A pathway from the Cyprus eHealth law to a citizen-centred national EHR prototype interoperable with myHealth@EU and international patient summary.

Digital health·2026
Same author

Clinical Validity of Circulating Tumor DNA as a Diagnostic Biomarker for Prostate Cancer: A Systematic Review.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants.

JACS Au·2026
Same author

Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020-2024).

Biomolecules·2026
Same author

Recent Advances in Dual COX/LOX Inhibitor Design (2020-2024): Establishing "<i>The Rule of Four for Inflammation</i>".

Life (Basel, Switzerland)·2026

Related Experiment Video

Updated: Apr 16, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

7.7K

LiSIs: An Online Scientific Workflow System for Virtual Screening.

Christos C Kannas1, Ioanna Kalvari, George Lambrinidis

  • 1Department of Computer Science, University of Cyprus, P.O. Box 20537, 1678 Nicosia, Cyprus. kannas.christos@ucy.ac.cy.

Combinatorial Chemistry & High Throughput Screening
|March 10, 2015
PubMed
Summary
This summary is machine-generated.

The Life Sciences Informatics (LiSIs) platform streamlines drug discovery using computational virtual screening (VS). This web-based system aids researchers in identifying promising chemical compounds through in silico methods, saving time and resources.

More Related Videos

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
06:29

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin

Published on: March 3, 2021

6.1K
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

215

Related Experiment Videos

Last Updated: Apr 16, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

7.7K
Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
06:29

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin

Published on: March 3, 2021

6.1K
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

215

Area of Science:

  • Computational chemistry and cheminformatics
  • Bioinformatics and computational biology
  • Drug discovery and development

Background:

  • Modern drug discovery increasingly relies on computational algorithms and virtual screening (VS) to accelerate the identification of potential drug candidates.
  • In silico methods offer a resource-efficient alternative to traditional experimental screening, reducing time and cost.
  • The development of integrated computational platforms is crucial for advancing drug discovery research.

Purpose of the Study:

  • To present the design and implementation of the Life Sciences Informatics (LiSIs) platform, a web-based system for virtual screening.
  • To demonstrate the utility of the LiSIs platform through case studies in Quantitative Structure-Activity Relationship (QSAR) modeling and docking-based virtual screening.
  • To provide drug discovery researchers with an accessible tool for employing advanced computational techniques.

Main Methods:

  • The LiSIs platform is structured in layers: input, pre-processing (descriptor calculation, docking preparation), processing (filtering, similarity, substructure matching, docking, predictive modeling, clustering), post-processing, and output.
  • Implementation involves a web-based scientific workflow system.
  • Two case studies were conducted: QSAR model development and a docking-based virtual screening experiment.

Main Results:

  • The LiSIs platform successfully facilitated the identification of promising chemical structures in both case studies.
  • Virtual screening workflows incorporating docking and predictive models within LiSIs aligned with expert expectations.
  • The platform's capabilities were demonstrated for QSAR modeling and docking-based screening.

Conclusions:

  • The LiSIs platform enables researchers to efficiently utilize state-of-the-art computational techniques for drug discovery.
  • The system's design supports the identification of promising chemical compounds through integrated in silico tools.
  • LiSIs is freely accessible, promoting wider adoption of advanced computational methods in the search for new drugs.